<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="314">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02547818</url>
  </required_header>
  <id_info>
    <org_study_id>AZT-001</org_study_id>
    <nct_id>NCT02547818</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease</brief_title>
  <acronym>COGNITE</acronym>
  <official_title>A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZTherapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaConsulting Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KCAS Bio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>APCER Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AZTherapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects&#xD;
      with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination&#xD;
      treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and&#xD;
      functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase III study is designed as a randomized, double-blinded, placebo-controlled study&#xD;
      for subjects with evidence of early AD. The study will evaluate safety and tolerability,&#xD;
      efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will&#xD;
      slow down, arrests, or reverse cognitive and functional decline in an early stage AD&#xD;
      population.&#xD;
&#xD;
      Subjects will be randomly assigned to one of four treatment arms: Group I will consist of&#xD;
      ALZT-OP1a (cromolyn) for inhalation, plus an oral placebo tablet; OR the Group II arm, which&#xD;
      will consist of ALZT-OP1 combination therapy ALZT-OP1a (cromolyn) for inhalation, plus&#xD;
      ALZT-OP1b (ibuprofen) tablet for oral administration; OR to the Group III arm, which will&#xD;
      consist of inhaled placebo, plus ALZT-OP1b (ibuprofen) tablet for oral administration; OR to&#xD;
      the Group IV placebo arm, which will consist of inhaled placebo plus an oral placebo tablet.&#xD;
&#xD;
      A minimum of 400 evaluable subjects will be randomized to receive one of four possible&#xD;
      treatment assignments containing various combinations of active study drug or placebo.&#xD;
&#xD;
      To account for subject dropouts (estimated rate of 30%), it is anticipated that up to 600 (or&#xD;
      150 subjects per treatment arm) may be recruited and randomized, to achieve a minimum of 100&#xD;
      evaluable subjects per treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2015</start_date>
  <completion_date type="Actual">November 18, 2020</completion_date>
  <primary_completion_date type="Actual">November 13, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Dementia Rating-Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline and Week 72</time_frame>
    <description>The combination active treatment group will be compared to each of the single component groups, including the placebo group, the mean change from Baseline to Week 72 will be quantified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>72 weeks</time_frame>
    <description>Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events. They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment. The AE's will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing is initiated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">620</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZT-OP1a</intervention_name>
    <description>1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Cromolyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALZT-OP1b</intervention_name>
    <description>Anti-inflammatory</description>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <other_name>Ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo ALZT-OP1a</intervention_name>
    <description>Non-active capsules</description>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo ALZT-OP1b</intervention_name>
    <description>Non-active tablets</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  55-79 years old;&#xD;
&#xD;
          -  ≥ 8 years of education;&#xD;
&#xD;
          -  Study partner is available who has frequent contact with the participant (e.g. an&#xD;
             average of 10 hours per week or more), and can accompany the participant to all clinic&#xD;
             visits for the duration of the protocol;&#xD;
&#xD;
          -  Evidence of early AD, as defined by all of the following:&#xD;
&#xD;
               1. Memory complaint by subject or study partner that is verified by a study partner;&#xD;
&#xD;
               2. Objective memory impairment for age, documented by scoring below the education&#xD;
                  adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from&#xD;
                  the Wechsler Memory Scale Third Edition (the maximum score is 25):&#xD;
&#xD;
                    -  ≤ 8 for 16 or more years of education, or&#xD;
&#xD;
                    -  ≤ 4 for 8-15 years of education;&#xD;
&#xD;
                    -  Essentially preserved general cognitive function;&#xD;
&#xD;
                    -  Largely intact functional activities;&#xD;
&#xD;
                    -  Not demented;&#xD;
&#xD;
          -  Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF&#xD;
             Aβ-42 levels ≥ 180 pg/mL and ≤ 690 pg/mL;&#xD;
&#xD;
          -  Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;&#xD;
&#xD;
          -  Must be fluent in the language of the cognitive testing material being administered;&#xD;
&#xD;
          -  Stability of permitted medications for 4 weeks prior to study start; subjects&#xD;
             receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of&#xD;
             those medications for at least 12 weeks prior to study start with every effort to&#xD;
             maintain stable dose for the duration of the study;&#xD;
&#xD;
          -  Visual and auditory acuity adequate for neuropsychological testing;&#xD;
&#xD;
          -  Good general health with no diseases expected to interfere with the study;&#xD;
&#xD;
          -  Must provide written informed consent for APOe4 genotype testing;&#xD;
&#xD;
          -  Must provide written informed consent for CSF sampling.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant neurological disease other than suspected incipient AD, such as&#xD;
             Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure&#xD;
             hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural&#xD;
             hematoma, multiple sclerosis, or history of significant head trauma followed by&#xD;
             persistent neurologic defaults or known structural brain abnormalities;&#xD;
&#xD;
          -  Major depressive episode, as described in the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty&#xD;
             complying with the protocol;&#xD;
&#xD;
          -  History of schizophrenia or bipolar disorder (DSM-IV criteria);&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV&#xD;
             criteria);&#xD;
&#xD;
          -  Currently taking medications that could lead to difficulty complying with the&#xD;
             protocol; subjects must be on a stable dose of current medications for 4 weeks prior&#xD;
             to study entry, with the exception of acetylcholinesterase inhibitors and/or&#xD;
             memantine, which must be on a stable dose for at least 12 weeks prior to study entry;&#xD;
&#xD;
          -  Investigational agents are prohibited one month prior to entry and for the duration of&#xD;
             the trial;&#xD;
&#xD;
          -  Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and&#xD;
             rifampicin);&#xD;
&#xD;
          -  Currently taking cromolyn, or have taken cromolyn, within the past 12 months;&#xD;
&#xD;
          -  Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or&#xD;
             other chronic inflammatory diseases (&quot;chronic&quot; defined as 3200 mg/day for &gt;2 weeks);&#xD;
&#xD;
          -  Chronic daily use of aspirin exceeding standard of care guidelines for low dose&#xD;
             aspirin therapy for prevention of stroke and/or other recommended uses;&#xD;
&#xD;
          -  Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.);&#xD;
&#xD;
          -  Allergies to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin;&#xD;
&#xD;
          -  Clinically significant respiratory disorders with impaired respiratory effort or&#xD;
             difficulty taking inhaled drugs;&#xD;
&#xD;
          -  Uncontrolled chronic asthma;&#xD;
&#xD;
          -  Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC &lt; predicted&#xD;
             value for subject AND FEV1 &lt; 70% of predicted value, indicating moderate or severe&#xD;
             respiratory obstruction;&#xD;
&#xD;
          -  Taking inhaled protein products on a chronic basis;&#xD;
&#xD;
          -  Any significant systemic illness or unstable medical condition which could lead to&#xD;
             difficulty complying with the protocol;&#xD;
&#xD;
          -  Pregnancy or lactation for female subjects of child-bearing potential (i.e., &lt; two&#xD;
             years post-menopausal or not surgically sterile);&#xD;
&#xD;
          -  For sexually active male subjects, unwillingness or incapability of using appropriate&#xD;
             contraception methods;&#xD;
&#xD;
          -  Severe renal or hepatic impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Elmaleh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AZTherapies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Territory Neurology &amp; Research Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Research Center</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renew Behavioral Health</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc.</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine School of Medicine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asclepes Research Center</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITrials</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Syrentys Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mile High Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TOPAZ Clinical Research</name>
      <address>
        <city>Apopka</city>
        <state>Florida</state>
        <zip>32703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease &amp; Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research Group</name>
      <address>
        <city>Greenacres City</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galiz Clinical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panax</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>22176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Phase Research Alliance - Cano Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Phase Research Alliance - MetroMed</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Phase Research Alliance</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies, Inc.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Research &amp; Wellness Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Health Care Associates</name>
      <address>
        <city>Schaumburg</city>
        <state>Illinois</state>
        <zip>60193</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Health Care</name>
      <address>
        <city>Freeport</city>
        <state>Maine</state>
        <zip>04032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel and Alexia Bratton Memory Clinic</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc.</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alzheimer's Disease Center</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Neurobehavioral Health</name>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <zip>49079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cognitive Clinical Trials</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research Inc.</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of America</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdvancedMed Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NeuroCognitive Institute</name>
      <address>
        <city>Mount Arlington</city>
        <state>New Jersey</state>
        <zip>07856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adirondack Medical Research Center</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manhattan Behavioral Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Network</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan S. Kline Institute for Psychiatric Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winifred Masterson Burke Medical Research Institute</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ANI Neurology, PLLC Alzheimer's Memory Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurological Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insight Clincial Trials</name>
      <address>
        <city>Shaker Heights</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulsa Clinical Research, Inc.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Clinical Research</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Neurological Associates, PA</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates of Arlington, P.A.</name>
      <address>
        <city>Mansfield</city>
        <state>Texas</state>
        <zip>76063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grayline Clinical Drug Trials</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wasatch Clinical Research, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingfisher Cooperative</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KaRa Institute of Neurological Diseases</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2113</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Private Clinic</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geelong Private Medical Centre</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMBAL &quot;Dr. Georgi Stranski&quot; EAD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Central Onco Hospital&quot; Ltd.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Ruse AD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;First MHAT - Sofia&quot; EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1154</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Aleksandrovska&quot; EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research</name>
      <address>
        <city>West Vancouver</city>
        <state>British Columbia</state>
        <zip>V7T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okanagan Clinical Trials</name>
      <address>
        <city>Kelowna</city>
        <state>Britsh Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Research Institute</name>
      <address>
        <city>Québec</city>
        <state>Montreal</state>
        <zip>H3A 284</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <zip>B4N 4K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JBN Medical</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham-Kent Clinical Trials</name>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <zip>N7l1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Memory and Aging</name>
      <address>
        <city>East York</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniuqe de la Memoire de l'Outouais</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T 8J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosanatio, s.r.o.</name>
      <address>
        <city>Litomyšl</city>
        <state>Czech Republic</state>
        <zip>570 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie MU - Ondrej Koci, s.r.o.</name>
      <address>
        <city>Novy Bor</city>
        <state>Czech Republic</state>
        <zip>473 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CT Center MaVfe, s.r.o</name>
      <address>
        <city>Olomouc</city>
        <state>Czech Republic</state>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestra Clinics, s.r.o.</name>
      <address>
        <city>Rychnov Nad Kněžnou</city>
        <state>Czech Republic</state>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROHK, s.r.o.</name>
      <address>
        <city>Chocen</city>
        <zip>565 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinline Services s.r.o.</name>
      <address>
        <city>Hostivice</city>
        <zip>253 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulance</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>503 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulance Supervize s.r.o.</name>
      <address>
        <city>Kutná Hora</city>
        <zip>28401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec a.s.</name>
      <address>
        <city>Liberec</city>
        <zip>460 63</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A-shine, s.r.o.</name>
      <address>
        <city>Plzen</city>
        <zip>312 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial.s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole Neurologicka klinika 2.LF UK a FN Motol</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INEP medical s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologia Klinika Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Klinikai Idegtudomanyi Intezat</name>
      <address>
        <city>Budapest</city>
        <zip>H-1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaszary Kolos Korhaz</name>
      <address>
        <city>Esztergom</city>
        <zip>H-2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Pandy Kalman Korhaz</name>
      <address>
        <city>Gyula</city>
        <zip>H-5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz</name>
      <address>
        <city>Győr</city>
        <zip>09024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cermed Pawel Hernik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podlaskie Centrum Psychogeriatrii</name>
      <address>
        <city>Bialystok</city>
        <zip>15-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychondnia Srodmiescie</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne KERMED</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Powiatowy w Czeladzi</name>
      <address>
        <city>Czeladz</city>
        <zip>41-250</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Psychicznego Biomed - Jan Latala</name>
      <address>
        <city>Kielce</city>
        <zip>25-411</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Kraków</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-Med</name>
      <address>
        <city>Ksawerow</city>
        <zip>95-054</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne im. Dr Karola Jonschera w Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>93-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC Sp. Zo.o.</name>
      <address>
        <city>Poznan</city>
        <zip>60-856</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromedis Sp. Zo.o</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.cognitetrial.com</url>
    <description>US Residents may click here to find out more about participation in this trial.</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2015</study_first_posted>
  <disposition_first_submitted>November 8, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>November 8, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 10, 2021</disposition_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early stage AD</keyword>
  <keyword>MCI</keyword>
  <keyword>aMCI</keyword>
  <keyword>prodromal</keyword>
  <keyword>Memory loss</keyword>
  <keyword>Memory problems</keyword>
  <keyword>Aging</keyword>
  <keyword>Early Alzheimer's Disease</keyword>
  <keyword>Early AD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

